Trial · NCT02623972
Results by group12
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 12 of 12
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Pathologic Complete Response Rate | Arm A: Eribulin followed by AC | 6.25 | 80% Confidence Interval 0.66 to 22.22 | percentage of participants | |
| Pathologic Complete Response Rate | Arm B: AC followed by Eribulin | 0 | 80% Confidence Interval 0 to 31.87 | percentage of participants | |
| Residual Cancer Burden (RCB) | Arm A: Eribulin followed by AC | RCB-0 | 6.25 | 80% Confidence Interval 0.66 to 22.22 | percentage of participants |
| Residual Cancer Burden (RCB) | Arm B: AC followed by Eribulin | RCB-0 | 0 | 80% Confidence Interval 0 to 31.87 | percentage of participants |
| Residual Cancer Burden (RCB) | Arm A: Eribulin followed by AC | RCB-I | 12.5 | 80% Confidence Interval 3.37 to 29.96 | percentage of participants |
| Residual Cancer Burden (RCB) | Arm B: AC followed by Eribulin | RCB-I | 0 | 80% Confidence Interval 0 to 31.87 | percentage of participants |
| Residual Cancer Burden (RCB) | Arm A: Eribulin followed by AC | RCB-II | 25 | 80% Confidence Interval 11.38 to 43.89 | percentage of participants |
| Residual Cancer Burden (RCB) | Arm B: AC followed by Eribulin | RCB-II | 50 | 80% Confidence Interval 20.09 to 79.91 | percentage of participants |
| Residual Cancer Burden (RCB) | Arm A: Eribulin followed by AC | RCB-III | 56.25 | 80% Confidence Interval 37.5 to 73.71 | percentage of participants |
| Residual Cancer Burden (RCB) | Arm B: AC followed by Eribulin | RCB-III | 33.33 | 80% Confidence Interval 9.26 to 66.68 | percentage of participants |
| Residual Cancer Burden (RCB) | Arm A: Eribulin followed by AC | Unknown | 0 | 80% Confidence Interval 0 to 13.4 | percentage of participants |
| Residual Cancer Burden (RCB) | Arm B: AC followed by Eribulin | Unknown | 16.67 | 80% Confidence Interval 1.74 to 51.03 | percentage of participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT02623972/results